All patients involved in the phase 1 trial of a personalized cancer vaccine for high-risk stage III/IV kidney cancer showed a successful anticancer immune response.
An enhanced model that integrates non-AJCC clinical features provides clinicians with a more accurate tool for identifying high-risk patients with MCC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback